

**South Dakota Department of Social Services, Division of Medicaid Services
Pharmacy & Therapeutics (P&T) Committee Meeting Minutes**

Friday, December 7, 2018

1:00 – 3:00 pm CT

Members and DSS Staff

Michelle Baack, MD	X	Kelley Oehlke, PharmD	X
Dana Darger, RPh, Chair	X	Lenny Petrik, PharmD	X
James Engelbrecht, MD	X	Timothy Soundy, MD	
Deidre Van Gilder, PharmD	X	Mike Jockheck, DSS Staff	X
Mikal Holland, MD	X	Sarah Akers, DSS Staff	X
Richard Holm, MD	X	Bill Snyder, DSS Staff	
Bill Ladwig, RPh	X		

Administrative Business

Darger called the meeting to order at 1:05 PM. The minutes of the June meeting were presented. Engelbrecht made a motion to approve. Oehlke seconded the motion. Motion was approved unanimously.

Prior Authorization Update (PA) and Statistics

The committee reviewed the PA activity report from July 1, 2018 to September 30, 2018. A total of 1,468 PAs were reviewed of which 286 requests (20%) were received via telephone and 1,182 requests (80%) were received via fax. Darger requested system capabilities to approve antipsychotic PAs more via electronic review. An in-depth review process for antipsychotics will be provided for the next meeting.

Analysis of the Top 15 Therapeutic Classes and Drug Spend

The committee reviewed the top 15 therapeutic classes by total cost of claims from July 1, 2018 to September 30, 2018. The top five therapeutic classes were atypical antipsychotics, insulins, respiratory and CNS stimulants, amphetamines, and disease-modifying anti-rheumatic agents. The top 15 therapeutic classes make up 27.70% of total claims. The committee also reviewed the top 50 drugs based on total claims cost and number of claims. The top 50 drugs by claims cost make up 12.11% of total claims. Darger commented on CiproDex utilization hitting the top 50 drug spend. Baack replied CiproDex is the preferred topical for ear tubes; Baack questioned its use for more otitis media or otitis external. Darger requested utilization data on CiproDex specifically prescriber information and member age. Baack will review literature.

Old Business

Committee reviewed CGRP utilization and fax form. Committee requested to review utilization again at the next meeting.

Committee reviewed Onfi utilization and Darger commented member count and utilization were appropriate.

Committee reviewed the PPI utilization and based on utilization data decided to revise the PPI PA/step therapy. Lansoprazole and omeprazole suspension will be removed from PA and they are to be used first before other PPI packets/suspensions/solutab for children less than 13 years old and members with

dysphagia. Prilosec pack (delayed release granules) will be added to step therapy. Holm made a motion to approve. Baack seconded the motion. Motion was approved unanimously. Engelbrecht suggested sending the updated PPI step therapy protocol information to all PPI prescribers.

The committee reviewed the estimated PDL savings. Darger was satisfied with the review.

New business

The committee reviewed utilization for respiratory drug utilization and were asked if other classes warranted in-depth review. Baack replied other classes had been reviewed in the past.

Committee was notified of the SUPPORT ACT. Jockheck commented he wanted to get it on the committee's radar and discuss it more in depth at future meetings.

Committee reviewed the anticonvulsant class, specifically Epidiolex and Diacomit. Both drugs are approved for Dravet Syndrome of which there are few options on the market. Committee recommended adding a similar PA to Onfi for Epidiolex. Engelbrecht made a motion to approve and Baack seconded the motion. The motion was approved unanimously.

The committee reviewed the anti-asthmatic monoclonal antibodies class and current PA for Nucala and Xolair. After reviewing the PA fax forms for Nucala and Xolair, committee recommended amending the criteria to add specialty consultation. Nucala requires prescribed or in consultation by rheumatologist, pulmonologist, allergist, or immunologist. Xolair requires prescribed or in consultation by dermatologist, rheumatologist, pulmonologist, allergist, or immunologist. Baack made a motion to approve and Ladwig seconded the motion. The motion was approved unanimously.

Committee recommended adding PA to Fasrena. Engelbrecht made a motion to approve and Holm seconded the motion. The motion was approved unanimously.

Akers discussed the DSS Boards Code of Conduct & Conflict of Interest to the committee. During the 2016 legislative session, the legislature developed the State Board of Internal Controls for all boards under DSS. The committee is being asked to review, discuss, and plan to adopt at this meeting or next meeting the DSS Boards Code of Conduct and Conflict of Interest. After review and discussion, Holm moved to accept the DSS Boards Code of Conduct and Conflict of Interest. Ladwig seconded the motion. All committee members were in favor and accepted.

The next meeting is scheduled on March 8, 2018. Tentative meeting date for June 2019 is June 21, 2019. Ladwig made a motion to adjourn. Holm seconded the motion. The meeting adjourned at 2:19 PM.